Proximity ligation assays for isoform-specific Akt activation in breast cancer identify activated Akt1 as a driver of progression
The PI3K/Akt signal transduction pathway plays an important role in cancer progression and cell survival. Akt activation is associated with poor outcome in endocrine‐treated breast cancer, whereas high levels of cytoplasmic Akt2 are associated with an improved overall survival. Proximity ligation as...
Saved in:
Published in | The Journal of pathology Vol. 227; no. 4; pp. 481 - 489 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Chichester, UK
John Wiley & Sons, Ltd
01.08.2012
Wiley |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The PI3K/Akt signal transduction pathway plays an important role in cancer progression and cell survival. Akt activation is associated with poor outcome in endocrine‐treated breast cancer, whereas high levels of cytoplasmic Akt2 are associated with an improved overall survival. Proximity ligation assays (PLAs) were used to determine quantitative expression levels of isoform‐specific activation (phosphorylation) of Akt1 and Akt2 in formalin‐fixed, paraffin‐embedded cell lines and breast cancer tumour tissues in situ. PLAs demonstrated a range of expression in breast cancer samples for total pAkt1 and pAkt2. High levels of pAkt1 were associated with reduced DRFS (HR: 1.45, 95% CI 1.14–1.83, p = 0.002) and OS (HR: 1.42, 95% CI 1.10–1.83, p = 0.007). When PLA results were combined, patients that had high levels of pAkt1 only had a significantly decreased DRFS (HR: 1.92, 95% CI 1.34–2.76, p = 0.005) and OS (HR: 1.94, 95% CI 1.32–2.86, p = 0.008) compared to other patients. Using PLAs to discriminate activation of Akt1 versus Akt2 suggests that Akt1 drives progression in early breast cancers. In cases where both Akt1/Akt2 are activated, Akt2 may act to reverse this effect. Using PLAs, we have measured activation of Akt1 and Akt2 proteins separately in situ in FFPE breast cancer samples. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. |
---|---|
AbstractList | The PI3K/Akt signal transduction pathway plays an important role in cancer progression and cell survival. Akt activation is associated with poor outcome in endocrine-treated breast cancer, whereas high levels of cytoplasmic Akt2 are associated with an improved overall survival. Proximity ligation assays (PLAs) were used to determine quantitative expression levels of isoform-specific activation (phosphorylation) of Akt1 and Akt2 in formalin-fixed, paraffin-embedded cell lines and breast cancer tumour tissues in situ. PLAs demonstrated a range of expression in breast cancer samples for total pAkt1 and pAkt2. High levels of pAkt1 were associated with reduced DRFS (HR: 1.45, 95% CI 1.14-1.83, p = 0.002) and OS (HR: 1.42, 95% CI 1.10-1.83, p = 0.007). When PLA results were combined, patients that had high levels of pAkt1 only had a significantly decreased DRFS (HR: 1.92, 95% CI 1.34-2.76, p = 0.005) and OS (HR: 1.94, 95% CI 1.32-2.86, p = 0.008) compared to other patients. Using PLAs to discriminate activation of Akt1 versus Akt2 suggests that Akt1 drives progression in early breast cancers. In cases where both Akt1/Akt2 are activated, Akt2 may act to reverse this effect. Using PLAs, we have measured activation of Akt1 and Akt2 proteins separately in situ in FFPE breast cancer samples. The PI3K/Akt signal transduction pathway plays an important role in cancer progression and cell survival. Akt activation is associated with poor outcome in endocrine‐treated breast cancer, whereas high levels of cytoplasmic Akt2 are associated with an improved overall survival. Proximity ligation assays (PLAs) were used to determine quantitative expression levels of isoform‐specific activation (phosphorylation) of Akt1 and Akt2 in formalin‐fixed, paraffin‐embedded cell lines and breast cancer tumour tissues in situ . PLAs demonstrated a range of expression in breast cancer samples for total pAkt1 and pAkt2. High levels of pAkt1 were associated with reduced DRFS (HR: 1.45, 95% CI 1.14–1.83, p = 0.002) and OS (HR: 1.42, 95% CI 1.10–1.83, p = 0.007). When PLA results were combined, patients that had high levels of pAkt1 only had a significantly decreased DRFS (HR: 1.92, 95% CI 1.34–2.76, p = 0.005) and OS (HR: 1.94, 95% CI 1.32–2.86, p = 0.008) compared to other patients. Using PLAs to discriminate activation of Akt1 versus Akt2 suggests that Akt1 drives progression in early breast cancers. In cases where both Akt1/Akt2 are activated, Akt2 may act to reverse this effect. Using PLAs, we have measured activation of Akt1 and Akt2 proteins separately in situ in FFPE breast cancer samples. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. The PI3K/Akt signal transduction pathway plays an important role in cancer progression and cell survival. Akt activation is associated with poor outcome in endocrine‐treated breast cancer, whereas high levels of cytoplasmic Akt2 are associated with an improved overall survival. Proximity ligation assays (PLAs) were used to determine quantitative expression levels of isoform‐specific activation (phosphorylation) of Akt1 and Akt2 in formalin‐fixed, paraffin‐embedded cell lines and breast cancer tumour tissues in situ. PLAs demonstrated a range of expression in breast cancer samples for total pAkt1 and pAkt2. High levels of pAkt1 were associated with reduced DRFS (HR: 1.45, 95% CI 1.14–1.83, p = 0.002) and OS (HR: 1.42, 95% CI 1.10–1.83, p = 0.007). When PLA results were combined, patients that had high levels of pAkt1 only had a significantly decreased DRFS (HR: 1.92, 95% CI 1.34–2.76, p = 0.005) and OS (HR: 1.94, 95% CI 1.32–2.86, p = 0.008) compared to other patients. Using PLAs to discriminate activation of Akt1 versus Akt2 suggests that Akt1 drives progression in early breast cancers. In cases where both Akt1/Akt2 are activated, Akt2 may act to reverse this effect. Using PLAs, we have measured activation of Akt1 and Akt2 proteins separately in situ in FFPE breast cancer samples. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. |
Author | Kunkler, Ian H Cunningham, Carrie A Jack, Wilma JL Taylor, Karen J Thomas, Jeremy St J Mallon, Elizabeth A Kerr, Gillian R Bartlett, John MS Spears, Melanie Chetty, Udi Cameron, David A |
Author_xml | – sequence: 1 givenname: Melanie surname: Spears fullname: Spears, Melanie organization: Transformative Pathology, Ontario Institute for Cancer Research, MaRS Centre, South Tower, 101 College St, Suite 800, Toronto, Ontario, Canada M5G 043 – sequence: 2 givenname: Carrie A surname: Cunningham fullname: Cunningham, Carrie A organization: Endocrine Cancer Research Group, Edinburgh Cancer Research Centre, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XR, UK – sequence: 3 givenname: Karen J surname: Taylor fullname: Taylor, Karen J organization: Edinburgh Breakthrough Breast Cancer Unit, Western General Hospital, Crewe Road South, Edinburgh, EH4 2XR, UK – sequence: 4 givenname: Elizabeth A surname: Mallon fullname: Mallon, Elizabeth A organization: Department of Pathology, Western Infirmary, Glasgow, G11 6NT, UK – sequence: 5 givenname: Jeremy St J surname: Thomas fullname: Thomas, Jeremy St J organization: Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, EH4 2XU, UK – sequence: 6 givenname: Gillian R surname: Kerr fullname: Kerr, Gillian R organization: Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, EH4 2XU, UK – sequence: 7 givenname: Wilma JL surname: Jack fullname: Jack, Wilma JL organization: Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, EH4 2XU, UK – sequence: 8 givenname: Ian H surname: Kunkler fullname: Kunkler, Ian H organization: Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, EH4 2XU, UK – sequence: 9 givenname: David A surname: Cameron fullname: Cameron, David A organization: Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, EH4 2XU, UK – sequence: 10 givenname: Udi surname: Chetty fullname: Chetty, Udi organization: Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, EH4 2XU, UK – sequence: 11 givenname: John MS surname: Bartlett fullname: Bartlett, John MS email: John.Bartlett@oicr.on.ca organization: Transformative Pathology, Ontario Institute for Cancer Research, MaRS Centre, South Tower, 101 College St, Suite 800, Toronto, Ontario, Canada M5G 043 |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26131783$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/22430898$$D View this record in MEDLINE/PubMed |
BookMark | eNp10E1v1DAQBmALFdFt4cAfQL4g0UNaf2UdH1cVdEEr6KGIozVxJsU0iRc7W5pj_zleZVtOnHyY552R3xNyNIQBCXnL2TlnTFxsYfx5rpgQL8iCM7MsTGWWR2SRZ6KQiutjcpLSL8aYMWX5ihwLoSSrTLUgj9cxPPjejxPt_C2MPgwUUoIp0TZE6lPIT1-kLTrfekdXdyMFN_r7mfqB1hEhjdTB4DAHGhxG305PCJt9hOedFGgT_X02oaXbGG4jppR3vCYvW-gSvjm8p-T7p483l-ti8-3q8-VqUzhVmvyNqqmbEgDQtbURpXJaclPzWhoFjiG6ugGJiuc5R4NMAgfdQMW0YCicPCUf5r359u8dptH2PjnsOhgw7JLlTCilNeNlpmczdTGkFLG12-h7iFNGdt-43Tdu941n--6wdlf32DzLp4ozeH8AkBx0bcxF-fTPLbnkupLZXczuj-9w-v9Fe726WR9OF3PCpxEfnhMQ7-xSS13aH1-v7JcN04qVyq7lXx_Fq94 |
CODEN | JPTLAS |
CitedBy_id | crossref_primary_10_1038_srep07758 crossref_primary_10_1186_1471_2407_14_762 crossref_primary_10_12677_SA_2018_72013 crossref_primary_10_1016_j_ejca_2012_12_006 crossref_primary_10_1002_path_4137 crossref_primary_10_1007_s00432_014_1663_x crossref_primary_10_1038_srep03538 crossref_primary_10_1111_cas_12637 crossref_primary_10_1681_ASN_2016070789 crossref_primary_10_4048_jbc_2022_25_e43 crossref_primary_10_1530_ERC_14_0232 crossref_primary_10_1016_j_bdq_2015_04_002 crossref_primary_10_1158_1541_7786_MCR_13_0219 crossref_primary_10_1016_j_taap_2023_116615 crossref_primary_10_1186_s12964_019_0450_3 crossref_primary_10_18632_oncotarget_24845 crossref_primary_10_1038_s41419_021_03680_1 crossref_primary_10_1002_path_4144 crossref_primary_10_1016_j_critrevonc_2016_01_013 crossref_primary_10_1200_JCO_2013_53_8272 crossref_primary_10_1111_jop_12211 crossref_primary_10_1007_s10549_012_2376_y crossref_primary_10_1038_srep44244 crossref_primary_10_1038_s41598_020_75529_0 crossref_primary_10_2217_bmt_14_35 |
Cites_doi | 10.1038/sj.onc.1206394 10.1038/sj.bjc.6605836 10.1038/nmeth947 10.1007/s10549-011-1426-1 10.1016/j.molonc.2010.10.002 10.1038/nbt0502-473 10.1002/path.1829 10.1186/bcr569 10.1002/ijc.21358 10.1007/s10549-006-9323-8 10.1111/j.1365-2559.2009.03429.x 10.1111/j.1365-2559.2006.02412.x 10.1007/s10549-011-1606-z 10.1158/1078-0432.CCR-06-1933 10.1210/me.2006-0068 10.1038/sj.bjc.6600126 10.1158/1078-0432.CCR-05-0196 10.1038/sj.bjc.6602678 |
ContentType | Journal Article |
Copyright | Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. 2015 INIST-CNRS |
Copyright_xml | – notice: Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. – notice: 2015 INIST-CNRS |
DBID | BSCLL IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1002/path.4022 |
DatabaseName | Istex Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1096-9896 |
EndPage | 489 |
ExternalDocumentID | 10_1002_path_4022 22430898 26131783 PATH4022 ark_67375_WNG_JL074054_H |
Genre | article Research Support, Non-U.S. Gov't Journal Article Comparative Study |
GrantInformation_xml | – fundername: The Sarah Percy Foundation – fundername: Breakthrough Breast Cancer |
GroupedDBID | --- -~X .3N .55 .GA .GJ .Y3 05W 0R~ 10A 123 1KJ 1L6 1OB 1OC 1ZS 29L 31~ 33P 3O- 3SF 3UE 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABLJU ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHMBA AI. AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EJD EMOBN F00 F01 F04 F5P FEDTE FUBAC G-S G.N GNP GODZA GSXLS H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M J5H JPC KBYEO KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES M68 MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MVM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OHT OIG OVD P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 QRW R.K RIWAO RJQFR ROL RWI RX1 SAMSI SUPJJ SV3 TEORI UB1 V2E VH1 W8V W99 WBKPD WH7 WHWMO WIB WIH WIJ WIK WJL WOHZO WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 XPP XV2 YQI YQJ ZGI ZXP ZZTAW ~IA ~KM ~WT 08R AAUGY AAVGM ABHUG ABWRO ACSMX ACXME ADAWD ADDAD AFVGU AGJLS IQODW ZA5 CGR CUY CVF ECM EIF NPM AAMNL AAYXX ACRPL CITATION 7X8 |
ID | FETCH-LOGICAL-c4592-38dbd5aaaecfb9254c7319b1b394ac0eecbda3e41ecf1e9e03a1a7da80720e2c3 |
IEDL.DBID | DR2 |
ISSN | 0022-3417 |
IngestDate | Wed Dec 04 15:10:06 EST 2024 Fri Dec 06 02:37:07 EST 2024 Sat Sep 28 07:49:38 EDT 2024 Sun Oct 22 16:04:46 EDT 2023 Sat Aug 24 00:58:52 EDT 2024 Wed Oct 30 09:53:44 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Keywords | Molecular form Breast disease Proximity Akt protein kinase Activation Breast cancer Malignant tumor Akt proximity ligation assay Assay Mammary gland diseases Anatomic pathology Ligature Cancer |
Language | English |
License | CC BY 4.0 Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4592-38dbd5aaaecfb9254c7319b1b394ac0eecbda3e41ecf1e9e03a1a7da80720e2c3 |
Notes | The Sarah Percy Foundation ark:/67375/WNG-JL074054-H ArticleID:PATH4022 Breakthrough Breast Cancer istex:F6A857C397FF35899085D6C006E9FBA462DF65AC No conflicts of interest were declared. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 22430898 |
PQID | 1024477015 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_1024477015 crossref_primary_10_1002_path_4022 pubmed_primary_22430898 pascalfrancis_primary_26131783 wiley_primary_10_1002_path_4022_PATH4022 istex_primary_ark_67375_WNG_JL074054_H |
PublicationCentury | 2000 |
PublicationDate | August 2012 |
PublicationDateYYYYMMDD | 2012-08-01 |
PublicationDate_xml | – month: 08 year: 2012 text: August 2012 |
PublicationDecade | 2010 |
PublicationPlace | Chichester, UK |
PublicationPlace_xml | – name: Chichester, UK – name: Chichester – name: England |
PublicationTitle | The Journal of pathology |
PublicationTitleAlternate | J. Pathol |
PublicationYear | 2012 |
Publisher | John Wiley & Sons, Ltd Wiley |
Publisher_xml | – name: John Wiley & Sons, Ltd – name: Wiley |
References | Spears M, Taylor KJ, Munro AF, et al. In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer. Breast Cancer Res Treat 2012; 132: 463-470. Kirkegaard T, Edwards J, Tovey S, et al. Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 2006; 48: 787-794. Kirkegaard T, Witton CJ, McGlynn LM, et al. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 2005; 207: 139-146. Likhite VS, Stossi F, Kim K, et al. Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol Endocrinol 2006; 20: 3120-3132. Kirkegaard T, McGlynn LM, Campbell FM, et al. Amplified in breast cancer 1 in human epidermal growth factor receptor-positive tumors of tamoxifen-treated breast cancer patients. Clin Cancer Res 2007; 13: 1405-1411. Thomas JS, Kerr GR, Jack WJ, et al. Histological grading of invasive breast carcinoma-a simplification of existing methods in a large conservation series with long-term follow-up. Histopathology 2009; 55: 724-731. Tokunaga E, Kimura Y, Oki E, et al. Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients. Int J Cancer 2006; 118: 284-289. Stal O, Perez-Tenorio G, Akerberg L, et al. Akt kinases in breast cancer and the results of adjuvant therapy. Breast Cancer Res 2003; 5: R37-R44. Soderberg O, Gullberg M, Jarvius M, et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nature Methods 2006; 3: 995-1000. Spears M, Oesterreich S, Migliaccio I, et al. The p160 ER co-regulators predict outcome in ER negative breast cancer. Breast Cancer Res Treat 2012; 131: 463-472. Aubele M, Spears M, Ludyga N, et al. In situ quantification of HER2-protein tyrosine kinase 6 (PTK6) protein-protein complexes in paraffin sections from breast cancer tissues. Br J Cancer 2010; 103: 663-667. Fredriksson S, Gullberg M, Jarvius J, et al. Protein detection using proximity-dependent DNA ligation assays. Nature Biotechnol 2002; 20: 473-477. Cannings E, Kirkegaard T, Tovey SM, et al. Bad expression predicts outcome in patients treated with tamoxifen. Breast Cancer Res Treat 2007; 102: 173-179. McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer 2005; 93: 387-391. Perez-Tenorio G, Stal O. Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer 2002; 86: 540-545. Knuefermann C, Lu Y, Liu B, et al. HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells. Oncogene 2003; 22: 3205-3212. Tovey S, Dunne B, Witton CJ, et al. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? Clin Cancer Res 2005; 11: 4835-4842. Vuoriluoto M, Laine LJ, Saviranta P, et al. Spatio-temporal composition of the mitotic Chromosomal Passenger Complex detected using in situ proximity ligation assay. Mol Oncol 2011; 5: 105-111. 2009; 55 2007; 102 2012; 131 2012; 132 2006; 20 2002; 86 2002; 20 2010; 103 2006; 48 2005; 207 2003; 5 2006; 3 2005; 93 2006; 118 2011; 5 2005; 11 2007; 13 2003; 22 23152120 - J Pathol. 2013 Feb;229(3):e2-3 23132205 - J Pathol. 2013 Feb;229(3):e1 e_1_2_7_5_2 e_1_2_7_4_2 e_1_2_7_3_2 e_1_2_7_2_2 e_1_2_7_9_2 e_1_2_7_8_2 e_1_2_7_7_2 e_1_2_7_6_2 e_1_2_7_19_2 e_1_2_7_18_2 e_1_2_7_17_2 e_1_2_7_16_2 e_1_2_7_15_2 e_1_2_7_14_2 e_1_2_7_13_2 e_1_2_7_12_2 e_1_2_7_11_2 e_1_2_7_10_2 |
References_xml | – volume: 11 start-page: 4835 year: 2005 end-page: 4842 article-title: Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer? publication-title: Clin Cancer Res – volume: 5 start-page: 105 year: 2011 end-page: 111 article-title: Spatio‐temporal composition of the mitotic Chromosomal Passenger Complex detected using proximity ligation assay publication-title: Mol Oncol – volume: 55 start-page: 724 year: 2009 end-page: 731 article-title: Histological grading of invasive breast carcinoma—a simplification of existing methods in a large conservation series with long‐term follow‐up publication-title: Histopathology – volume: 86 start-page: 540 year: 2002 end-page: 545 article-title: Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients publication-title: Br J Cancer – volume: 5 start-page: R37 year: 2003 end-page: R44 article-title: Akt kinases in breast cancer and the results of adjuvant therapy publication-title: Breast Cancer Res – volume: 20 start-page: 473 year: 2002 end-page: 477 article-title: Protein detection using proximity‐dependent DNA ligation assays publication-title: Nature Biotechnol – volume: 207 start-page: 139 year: 2005 end-page: 146 article-title: AKT activation predicts outcome in breast cancer patients treated with tamoxifen publication-title: J Pathol – volume: 20 start-page: 3120 year: 2006 end-page: 3132 article-title: Kinase‐specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity publication-title: Mol Endocrinol – volume: 22 start-page: 3205 year: 2003 end-page: 3212 article-title: HER2/PI‐3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells publication-title: Oncogene – volume: 131 start-page: 463 year: 2012 end-page: 472 article-title: The p160 ER co‐regulators predict outcome in ER negative breast cancer publication-title: Breast Cancer Res Treat – volume: 102 start-page: 173 year: 2007 end-page: 179 article-title: Bad expression predicts outcome in patients treated with tamoxifen publication-title: Breast Cancer Res Treat – volume: 3 start-page: 995 year: 2006 end-page: 1000 article-title: Direct observation of individual endogenous protein complexes by proximity ligation publication-title: Nature Methods – volume: 48 start-page: 787 year: 2006 end-page: 794 article-title: Observer variation in immunohistochemical analysis of protein expression, time for a change? publication-title: Histopathology – volume: 132 start-page: 463 year: 2012 end-page: 470 article-title: detection of HER2:HER2 and HER2:HER3 protein–protein interactions demonstrates prognostic significance in early breast cancer publication-title: Breast Cancer Res Treat – volume: 13 start-page: 1405 year: 2007 end-page: 1411 article-title: Amplified in breast cancer 1 in human epidermal growth factor receptor‐positive tumors of tamoxifen‐treated breast cancer patients publication-title: Clin Cancer Res – volume: 103 start-page: 663 year: 2010 end-page: 667 article-title: quantification of HER2‐protein tyrosine kinase 6 (PTK6) protein–protein complexes in paraffin sections from breast cancer tissues publication-title: Br J Cancer – volume: 93 start-page: 387 year: 2005 end-page: 391 article-title: REporting recommendations for tumour MARKer prognostic studies (REMARK) publication-title: Br J Cancer – volume: 118 start-page: 284 year: 2006 end-page: 289 article-title: Akt is frequently activated in HER2/neu‐positive breast cancers and associated with poor prognosis among hormone‐treated patients publication-title: Int J Cancer – ident: e_1_2_7_7_2 doi: 10.1038/sj.onc.1206394 – ident: e_1_2_7_10_2 doi: 10.1038/sj.bjc.6605836 – ident: e_1_2_7_9_2 doi: 10.1038/nmeth947 – ident: e_1_2_7_14_2 doi: 10.1007/s10549-011-1426-1 – ident: e_1_2_7_19_2 doi: 10.1016/j.molonc.2010.10.002 – ident: e_1_2_7_18_2 doi: 10.1038/nbt0502-473 – ident: e_1_2_7_2_2 doi: 10.1002/path.1829 – ident: e_1_2_7_4_2 doi: 10.1186/bcr569 – ident: e_1_2_7_5_2 doi: 10.1002/ijc.21358 – ident: e_1_2_7_8_2 doi: 10.1007/s10549-006-9323-8 – ident: e_1_2_7_12_2 doi: 10.1111/j.1365-2559.2009.03429.x – ident: e_1_2_7_16_2 doi: 10.1111/j.1365-2559.2006.02412.x – ident: e_1_2_7_11_2 doi: 10.1007/s10549-011-1606-z – ident: e_1_2_7_15_2 doi: 10.1158/1078-0432.CCR-06-1933 – ident: e_1_2_7_6_2 doi: 10.1210/me.2006-0068 – ident: e_1_2_7_3_2 doi: 10.1038/sj.bjc.6600126 – ident: e_1_2_7_13_2 doi: 10.1158/1078-0432.CCR-05-0196 – ident: e_1_2_7_17_2 doi: 10.1038/sj.bjc.6602678 |
SSID | ssj0009955 |
Score | 2.2357373 |
Snippet | The PI3K/Akt signal transduction pathway plays an important role in cancer progression and cell survival. Akt activation is associated with poor outcome in... |
SourceID | proquest crossref pubmed pascalfrancis wiley istex |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 481 |
SubjectTerms | Akt Biological and medical sciences breast cancer Breast Neoplasms - metabolism Breast Neoplasms - physiopathology Cohort Studies Disease Progression Female Gynecology. Andrology. Obstetrics Humans Investigative techniques, diagnostic techniques (general aspects) Mammary gland diseases Medical sciences Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques Phosphorylation - physiology Prognosis Protein Isoforms - metabolism Proto-Oncogene Proteins c-akt - metabolism proximity ligation assay Reproducibility of Results Tumors |
Title | Proximity ligation assays for isoform-specific Akt activation in breast cancer identify activated Akt1 as a driver of progression |
URI | https://api.istex.fr/ark:/67375/WNG-JL074054-H/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fpath.4022 https://www.ncbi.nlm.nih.gov/pubmed/22430898 https://search.proquest.com/docview/1024477015 |
Volume | 227 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bi9QwFD4sK4gv3nXrZYki4ktnmzSdtPg0qOuwuMsiu7gPQsmtsIy0MtMBxyfBP-Bv9Jd4TjPtMKIgvhWa0zTJOe2X5DtfAJ6JYqy8KHBuwq2PpctEjDDEx1ynLhcOoyuj3OHjk_H0XB5dZBc78LLPhQn6EMOCG0VG972mANdmcbARDaUTe0c4-6HvL08V0flev99IRxVFlg1K4ZKrXlUoEQeD5da_6Ap16xfiRuoFdk8VzrX4E_DcxrHdj-jwBnzsmxD4J7PRsjUj-_U3dcf_bONNuL4GqGwSPOoW7Pj6Nlw9Xm_B34Hvp1gxZUWt2KdOnqOpGQJwvVowxL_sctEQDP757QflcBIPiU1mLaP0ibD4yy5rZogJ3zJLHocmXa5wteoLeUcmHJ_KNHNzIo6wpmIdkyyoiNyF88M3Z6-m8fokh9jKrMAByJ1xmdba28oUOCe1CkPfcJMWUtvEe2ucTr3keJ_7wiep5lo5nSdKJF7Y9B7s1k3t94BxJ02i3VhYLWn6lzuXOuGzsTSVkpWI4Gk_puXnINhRBmlmUVJ3ltSdETzvRnsooeczYriprPxw8rY8eofACrFsOY1gf8sdBgOsGZFXnkbwpPePEgOTdlt07ZvlAmtE5KQUwq0I7gfH2VgLmSZ5kUfwohv-v79peTo5m9LFg38v-hCuIawTgab4CHbb-dI_RujUmv0uRn4B2M0YFA |
link.rule.ids | 314,780,784,1375,27924,27925,46294,46718 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bi9QwFA7LLqgv3i9ddY0i4ktnmzSdtuDLoK51nRkWmcV9WUJuhWWkXeYCjk-Cf8Df6C_xnGbaYURBfCs0p2mTc5Iv6Xe-EPKc5_3U8RzWJsy4UNiEhwBDXMhUbDNuIboSzB0ejfvFqTg-S852yKs2F8brQ3QbbhgZzXiNAY4b0ocb1VA8srcHyx8YgPcg3BkSut583IhH5XmSdFrhgqWtrlDEDzvTrdloDxv2C7Ij1RwaqPQnW_wJem4j2WYqOrpBztuP8AyUaW-50D3z9Td9x__9ypvk-hqj0oF3qltkx1W3yZXR-i_8HfL9BGrGxKgV_dwodNQVBQyuVnMKEJhezGtEwj-__cA0TqQi0cF0QTGDwu__0ouKaiTDL6hBpwOTJl24XLWFnEUTBk-litoZckdoXdKGTOaFRO6S06O3k9dFuD7MITQiyaEHMqttopRyptQ5LEtNCtGvmY5zoUzknNFWxU4wuM9c7qJYMZValUUpjxw38T2yW9WVe0Aos0JHyva5UQJXgJm1seUu6QtdpqLkAXnWdqq89Jod0qszc4nNKbE5A_Ki6e6uhJpNkeSWJvLT-J08HgK2Ajgri4AcbPlDZwA1A_jK4oA8bR1EQmziDxdVuXo5hxoBPKUpIK6A3Pees7HmIo6yPAvIy6b___6m8mQwKfBi_9-LPiFXi8loKIfvxx8ekmuA8rhnLT4iu4vZ0j0GJLXQB03A_AJF8hw1 |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1fb9MwELemTZp44T8sGwyDEOIlXeI4TSyeKkYpY6sqtIk9IFn-F2kqSqY2lShPSHwBPiOfhLu4SVUEEuItUnxxbN_Zv7PvfibkORP9zDEBvklsXMhtykKAIS6MVWJzZsG6UswdPhv3Rxf85DK93CKv2lwYzw_RbbihZTTzNRr4tS2O1qSheGNvD7wfmH93eJ8JJM4__rDmjhIiTTuqcB5nLa1QxI460Y3FaAf79QsGR6o59E_hL7b4E_LcBLLNSjS8RT61bfABKNPeotY98_U3esf_bORtcnOFUOnAq9QdsuXKu2T3bHUGf498n0DFmBa1pJ8bfo6qpIDA1XJOAQDTq3mFOPjntx-YxImBSHQwrSnmT_jdX3pVUo2h8DU1qHIg0iQLF8u2kLMoEsNXqaJ2hpEjtCpoE0rmaUTuk4vhm_PXo3B1lUNoeCpgAHKrbaqUcqbQApxSk4Ht61gngisTOWe0VYnjMbyPnXBRomKVWZVHGYscM8kDsl1WpdsjNLZcR8r2mVEc_b_c2sQyl_a5LjJesIA8a8dUXnvGDum5mZnE7pTYnQF50Yx2V0LNphjilqXy4_itPDkFZAVgVo4CcrihDp0A1AzQK08C8rTVDwmWicctqnTVYg41AnTKMsBbAXnoFWctzXgS5SIPyMtm-P_-p3IyOB_hw_6_F31CdifHQ3n6bvz-gNwAiMd8yOIjsl3PFu4xwKhaHzbm8gvtSxrk |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Proximity+ligation+assays+for+isoform-specific+Akt+activation+in+breast+cancer+identify+activated+Akt1+as+a+driver+of+progression&rft.jtitle=The+Journal+of+pathology&rft.au=Spears%2C+Melanie&rft.au=Cunningham%2C+Carrie+A&rft.au=Taylor%2C+Karen+J&rft.au=Mallon%2C+Elizabeth+A&rft.date=2012-08-01&rft.pub=John+Wiley+%26+Sons%2C+Ltd&rft.issn=0022-3417&rft.eissn=1096-9896&rft.volume=227&rft.issue=4&rft.spage=481&rft.epage=489&rft_id=info:doi/10.1002%2Fpath.4022&rft.externalDBID=n%2Fa&rft.externalDocID=ark_67375_WNG_JL074054_H |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-3417&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-3417&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-3417&client=summon |